Phase 1, Open-Label, Multicenter Study of Intramuscular PRL-02 Depot in Patients With Advanced Prostate Cancer
Latest Information Update: 13 Oct 2025
At a glance
- Drugs Abiraterone decanoate (Primary) ; Dexamethasone; Docetaxel; Prednisone; Steroids
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions; First in man
- Sponsors Astellas Pharma; Propella Therapeutics
Most Recent Events
- 25 Sep 2025 Planned primary completion date changed from 31 Aug 2025 to 31 May 2029.
- 13 Dec 2024 Planned End Date changed from 30 Apr 2025 to 31 May 2029.
- 13 Dec 2024 Planned primary completion date changed from 31 Dec 2024 to 31 Aug 2025.